- Global Pharma News & Resources

MYM Subsidiary, Sublime Culture Inc., Receives Cannabis Cultivation License From Health Canada

VANCOUVER, British Columbia, Feb. 1, 2020 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (OTC: MYMMF) (CSE: MYM.CN) (MYM.CN) ("MYM" or "The Company") is pleased to announce its subsidiary, Sublime Culture Inc., has received a cultivation license from Health Canada to produce cannabis at its indoor facility located in Laval, Quebec.

The Laval facility is a cutting edge, highly optimized, indoor facility that is complete and ready to cultivate high-quality, specialty "craft" cannabis varieties. Included is a mothering and cloning area allowing for exceptional genetic development and archiving.

"We are extremely excited to receive our cultivation license for the Sublime facility in Laval, Quebec. We are eager to put our team to work on cultivating small batch, super premium, indoor cannabis," said Howard Steinberg, CEO of MYM.

About MYM Nutraceuticals Inc.

MYM is uniquely positioned to opportunistically acquire and/or invest in companies within the cannabis and hemp industries that are in need of capital and management support. Our senior management team is made up of experts engaged in a wide array of disciplines – upper level management of public companies, finance, law, master growing, plant pathology, agricultural economics, pharmaceutical, engineering, global marketing, product development and branding, distribution and seed genetics. MYM is a shareholder in two production projects in Quebec and is actively looking to acquire complementary businesses and assets in the cannabis sector. MYM shares trade in Canada, Germany and the United States under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).


Howard Steinberg, CEO
MYM Nutraceuticals Inc.

Investor Relations

Keep up to date with MYM on our social media channels:

Twitter: @mymnutra
Facebook: @mymnutra
Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.


View original content:

SOURCE MYM Nutraceuticals Inc.

Editor Details

Last Updated: 01-Feb-2020